US Patent 10966985 Macrocyclic compounds as ROS1 kinase inhibitors

Patent 10966985 was granted and assigned to Array Biopharma Inc. on April, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Array Biopharma Inc.

Current Assignee

Array Biopharma Inc.

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

10966985

Date of Patent

April 6, 2021

Patent Application Number

16199818

Date Filed

November 26, 2018

Patent Citations

‌

US Patent 10137127 Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

‌

US Patent 10030005 Inhibitors of RET

‌

US Patent 10172861 Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate

Patent Primary Examiner

‌

Savitha M Rao

Patent abstract

Methods for inhibiting a ROS1 kinase with compounds of Formula I:

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10966985 Macrocyclic compounds as ROS1 kinase inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API